Basilea Pharmaceutica AG BPMUF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.69M | 17.83M | 15.29M | 15.27M | 9.58M |
| Total Depreciation and Amortization | 630.90K | 636.00K | 1.78M | 1.78M | 586.70K |
| Total Amortization of Deferred Charges | 122.80K | 123.80K | 76.40K | 76.30K | 221.80K |
| Total Other Non-Cash Items | 4.26M | 4.29M | 1.40M | 1.40M | 3.96M |
| Change in Net Operating Assets | -10.69M | -10.77M | 5.87M | 5.87M | -376.40K |
| Cash from Operations | 12.01M | 12.10M | 24.43M | 24.40M | 13.98M |
| Capital Expenditure | -258.80K | -260.90K | -1.44M | -1.44M | -194.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.80K | -23.00K | -93.30K | -93.10K | -56.40K |
| Cash from Investing | -281.60K | -283.90K | -1.53M | -1.53M | -250.90K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 192.50K | 192.50K | 92.50K | 92.50K | 253.50K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.63M | -2.63M | -3.57M | -3.57M | -7.49M |
| Cash from Financing | -3.09M | -3.11M | -4.35M | -4.35M | -8.77M |
| Foreign Exchange rate Adjustments | -7.00K | -7.00K | -9.40K | -9.40K | -6.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.63M | 8.70M | 18.54M | 18.51M | 4.95M |